The global plasmapheresis machines market was valued at USD 1.61 billion in 2025 and is projected to grow from USD 1.74 billion in 2026 to USD 3.17 billion by 2034, registering a 7.8% CAGR during 2026–2034. North America dominated the market with a 38.6% share in 2025, while Asia Pacific is expected to register the fastest growth at a 9.6% CAGR during the forecast period.
Market Size (2025): USD 1.61 Billion
Market Size (2026): USD 1.74 Billion
CAGR (Forecast Period): 7.8%
Forecast Year: 2034
Projected Market Size (2034): USD 3.17 Billion
Dominant Region: North America – 38.6%
Fastest Growing Region: Asia Pacific – 9.6% CAGR
Market Overview
Plasmapheresis machines separate plasma from blood and support both plasma collection and therapeutic plasma exchange. Their use spans blood donation centers, hospitals, clinics, and specialized apheresis facilities, where reliable separation, processing efficiency, donor safety, and treatment consistency are important operational priorities.
Technology development is also moving toward more controlled and automated plasma processing. FDA clearance in 2025 for a Fresenius Kabi Aurora Xi software update and a 2026 clearance for the Plasmacell-C disposable set illustrate continued innovation in membrane-based collection and single-use processing workflows.
Growth Drivers
A broader clinical need for therapeutic plasma exchange is supporting equipment adoption in hospitals and specialized treatment centers. A 2025 clinical study from western India reported that neurological conditions represented 76.9% of patients receiving therapeutic plasma exchange, while a separate 2025 report from Jehangir Hospital documented 152 procedures, demonstrating the use of apheresis equipment in tertiary-care settings.
Expansion of dedicated apheresis infrastructure further strengthens the installed base of plasmapheresis machines. Hospitals with specialized transfusion medicine and apheresis units can handle repeated plasma-exchange procedures while improving access to treatment for patients with complex neurological, autoimmune, and hematologic conditions.
Market Challenges
High equipment, maintenance, and servicing costs can make advanced plasmapheresis systems difficult to procure for smaller hospitals and newly established apheresis centers. Capital requirements can delay equipment replacement and restrict the development of specialized plasma-treatment units, particularly in cost-sensitive healthcare systems.
A shortage of professionals trained in apheresis procedures can also constrain machine utilization. Specialized operating skills and maintenance expertise increase staffing requirements and can make it difficult for healthcare facilities to establish new services at full capacity.
Market Opportunities
Emerging healthcare markets offer manufacturers, private hospitals, and apheresis service providers opportunities to expand equipment installations, maintenance contracts, and operator-training services. Terumo BCT's additional therapeutic apheresis approvals across 14 Latin American countries in 2025 demonstrate the potential for geographic expansion of specialized apheresis applications.
Critical-care applications provide another revenue avenue for medical-device manufacturers and specialized healthcare providers. The 2025 collaboration between Terumo BCT and Santersus to advance therapeutic apheresis technology for sepsis treatment illustrates how new clinical applications can broaden the use of apheresis systems beyond conventional plasma collection.
Segment Analysis
By collection type, the Plasma Collection System segment accounted for 61.5% of the market in 2025, due to its established use across plasma collection procedures and blood centers. The Multi-Component Collection System segment is expected to grow at a 8.1% CAGR during 2026–2034, driven by its ability to collect multiple blood components from a single donation and improve donor utilization.
By technology, Centrifugation-Based Plasmapheresis held a 58.7% share in 2025, owing to its established use, efficient blood-component processing, and broad adoption across therapeutic and donation settings. Membrane Filtration-Based Plasmapheresis is projected to grow at an 8.4% CAGR, fueled by selective separation capabilities and controlled plasma processing.
By application, Plasma Donation accounted for 46.1% of the market in 2025 and is expected to grow at an 8.2% CAGR through 2034, supported by plasma collection for transfusion, plasma-derived therapies, and blood-component management.
By end user, Hospitals and Clinics represented 39.4% of the market in 2025, while Home Care Settings are expected to record the fastest growth at an 8.9% CAGR, driven by broader adoption of home-based healthcare and portable therapeutic solutions.
Regional Analysis
North America accounted for the largest regional share of 38.6% in 2025, supported by substantial plasma-collection capacity, advanced blood-processing infrastructure, and established use of plasma-derived therapies. In 2026, the U.S. FDA reported that domestic collectors obtain more than 50 million liters of Source Plasma annually and supply more than 70% of the global Source Plasma used for plasma therapeutics.
Asia Pacific is expected to grow at a CAGR of 9.6% during 2026–2034, showcasing the fastest-growing regional market. Expansion of blood-component collection facilities and improvements in transfusion infrastructure are supporting the regional outlook, with Japan, China, South Korea, and India strengthening their respective blood and plasma management frameworks.
Europe accounted for 27.4% of the market in 2025 and is projected to grow at a 7.1% CAGR. Demand for plasma-derived medicines, collection programs, and improved apheresis capabilities continues to support opportunities across major European healthcare markets.
Competitive Landscape
The plasmapheresis machines market is moderately concentrated, with medical-device manufacturers, blood-processing technology companies, apheresis specialists, and regional medical-technology providers competing across plasma collection and therapeutic applications. Competition centers on clinical performance, device reliability, plasma yield, processing speed, safety, regulatory compliance, disposable compatibility, installed base, automation, and technical support.
Key companies include:
Baxter International Inc.
Charles River Laboratories Inc.
Fresenius Medical Care
Haemonetics Corporation
Terumo BCT Inc.
Asahi Kasei
Nikkiso
B. Braun Melsungen AG
Nigale Biomedical Inc.
Kawasumi Laboratories
Scinomed
Shanghai Dahua Medical Apparatus Co., Ltd.
Infomed SA
Recent Developments
In March 2026, Terumo Blood and Cell Technologies introduced its APAC Cell & Gene Therapy Ecosystem Blueprint, a collaborative framework designed to support the adoption of advanced apheresis and cell-processing technologies across Asia Pacific.
In February 2026, SunCoast Blood Centers became the first blood center in Florida and the ninth in the U.S. to deploy Terumo BCT's FDA-cleared Reveos Automated Blood Processing System, expanding automation in blood and plasma processing operations.
In September 2025, CSL Plasma and Terumo Blood and Cell Technologies completed the nationwide rollout of the Rika Plasma Donation System across all CSL Plasma centers in the U.S., with more than 300 centers deploying the system to support plasma collection and donor care.
Haemonetics continues to develop integrated plasma collection technologies through its NexSys PCS platform, which combines automated device functions with donor-management and workflow software to improve collection efficiency, compliance, and donor experience.
Click to Read the Complete Insights & Report: https://straitsresearch.com/report/plasmapheresis-machines-market
Future Outlook
The plasmapheresis machines market is expected to benefit from the continued expansion of plasma collection infrastructure, therapeutic plasma exchange, and plasma-derived therapies. Automation, membrane filtration, single-use processing sets, and connected workflow technologies are likely to remain important areas of product development.
Manufacturers can strengthen their market position by improving plasma yield, donor comfort, procedural safety, equipment efficiency, and service support. Expansion into emerging healthcare markets and new therapeutic applications can also create additional opportunities for equipment suppliers and specialized apheresis providers.
About Straits Research
Straits Research is a global market intelligence and consulting company that provides research reports, strategic insights, competitive analysis, and advisory services across multiple industries. Its research supports businesses, investors, and decision-makers in evaluating market dynamics, identifying opportunities, and developing informed growth strategies.
You Might Like Also
